Revive (RVVTF) Hits a Snag?

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 First our summary."FDA provided communication that...
Dr John Fahy UCSF

Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...

What is NAC (N-Acetyl-L-Cysteine)? (Dr Eric Berg)

https://youtu.be/oPdGOrqTfhA What is NAC good for? (and How Much to Take?)

FDA Issues Final ‘Enforcement Discretion’ Guidance on NAC.

NAC Crosses Major Hurdle With FDA. Is Bucillamine Next. Josh Long | Aug 01, 2022 "Industry, and...

Revive Therapeutics (RVVTF) Enters the Danger Zone.

What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock.

Revive’s Quarterly Report, Discussion, and a Video!

With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it....
Revive Therapeutics

Revive Therapeutics Gains 25% on Positive FDA Comments.

The Company stated yesterday that it "has received positive comments from the FDA in regard to the Company’s request to determine and...

Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?

Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Revive Therapeutics

Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...

Two Binary Events Directly Ahead. As in Months Away, not Years. Share Price up 76% During April.

Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...

New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.

Latest article

Iconic Brands (ICNB) Reports Revenues of $13.8 Million vs $4 Million. Bounces 40% Intraday.

After a Rough Six Months in the market, Nine Month Numbers Propels the Stock 40% Higher Signaling Possible Bottoming Process. ...

Adding Silo Pharma (SILO) $3.50 to Watch List.

Look What We Found! We launched the Psychedelic Stock Review a little more than a year ago and decided...

Alzheimer Drug Trials

A winner is crowned in head-to-head Alzheimer's battle between Biogen's Aduhelm and Lilly - Dec 1, 2022 Eli...